카이버나 테라퓨틱스(KYTX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $7.13 (+1.28%), 시가총액 $0.54B, 52주 최저~최고 $2.27 ~ $11.25.
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAI
카이버나 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
카이버나 테라퓨틱스의 현재 주가는 $7.13 (+1.28%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
카이버나 테라퓨틱스의 시가총액은 약 $0.54B입니다.
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD1